Bard buys Californian bulking agent firm Genyx:
This article was originally published in Clinica
Executive Summary
CR Bard has agreed to buy Genyx Medical, a private firm based in Aliso Viejo, California, that makes and markets an alternative treatment to surgery for stress urinary incontinence. For an undisclosed sum, it has acquired the assets related to Uryx, a CE marked bulking agent that is injected into the area surrounding the female urethra to support the urinary sphincter. The product is in late-stage trials in the US and Genyx expects to file for pre-market approval in the first half of this year. Bard already markets a collagen implant, Contigen, to treat the condition.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.